Last $0.02 USD
Change Today +0.002 / 12.90%
Volume 56.9K
TNGN On Other Exchanges
Symbol
Exchange
OTC US
As of 11:32 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

tengion inc (TNGN) Snapshot

Open
$0.02
Previous Close
$0.02
Day High
$0.02
Day Low
$0.02
52 Week High
10/21/13 - $0.60
52 Week Low
10/14/14 - $0.02
Market Cap
438.4K
Average Volume 10 Days
288.6K
EPS TTM
$-3.53
Shares Outstanding
25.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TENGION INC (TNGN)

Related News

No related news articles were found.

tengion inc (TNGN) Related Businessweek News

No Related Businessweek News Found

tengion inc (TNGN) Details

Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children’s Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina.

25 Employees
Last Reported Date: 04/9/14
Founded in 2003

tengion inc (TNGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $462.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $336.6K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $380.8K
Compensation as of Fiscal Year 2013.

tengion inc (TNGN) Key Developments

Tengion, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014; Provides Clinical Update

Tengion, Inc. announced unaudited earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $4,078,000, net loss of $11,935,000 or $3.59 per basic and diluted share, adjusted net loss of $5,815,000 or $1.75 per basic and diluted share compared to the loss from operations of $4,809,000, net loss of $17,855,000 or $0.82 per basic and diluted share, adjusted net loss of $6,534,000 or $0.3 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported loss from operations of $8,221,000, net loss of $17,709,000 or $5.84 per basic and diluted share, adjusted net loss of $11,350,000 or $3.74 per basic and diluted share compared to the loss from operations of $9,218,000, net loss of $53,113,000 or $2.96 per basic and diluted share, adjusted net loss of $12,745,000 or $0.72 per basic and diluted share for the same period a year ago. The company announced six-month interim data for the first five patients with advanced CKD implanted in the Phase 1 clinical trial being conducted at the Karolinska Institute in Stockholm, Sweden. NKA cellular therapy was successfully implanted into one kidney of each patient. Four surgical procedure-related serious adverse events were recorded in this trial. None of these events were determined to be related to the NKA material and none caused the patients to discontinue the trial or the Data Safety Monitoring Board to stop the trial. None of the reported adverse events were kidney-related. The company has completed enrollment in its ongoing Phase 1 clinical trial for the Neo-Urinary Conduit. Bladder cancer patients were enrolled in the trial to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to translate the surgical implantation procedure utilized in preclinical studies. The Company is working with key opinion leaders on future development plans for the Neo-Urinary Conduit, and will seek to execute a strategic or financial transaction to provide targeted funding for future development of the Neo-Urinary Conduit. In the absence of such funding, the Company does not plan to continue independent development of the Neo-Urinary Conduit program.

Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Tengion, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported loss from operations of $4,409,000 against $4,143,000 for the same period a year ago. Net loss was $34,258,000 or $1.91 per share basic and diluted against $5,774,000 or $2.11 loss per share basic and diluted for the same period a year ago. Adjusted net loss was $6,211,000 or $0.35 loss per share against $5,535,000 or $2.02 for the same period a year ago. The increase in research and development expense was primarily due to an increase in compensation and related expenses resulting from additional employees and an increased use of clinical and regulatory consultants, as well as an increase in external services related to the clinical trials for the Neo-Kidney Augment program. The increased adjusted net loss was primarily due to an increase in research and development expense of $0.3 million and an increase in interest expense of $0.5 million, offset in part by a decrease in general and administrative expense of $0.1 million.

Tengion, Inc., Annual General Meeting, May 02, 2014

Tengion, Inc., Annual General Meeting, May 02, 2014., at 12:30 US Eastern Standard Time. Location: Philadelphia Airport Marriott, One Arrivals Road. Agenda: To elect three Class I Directors for a three-year term expiring at the 2017 Annual Meeting; to ratify the selection by the Audit Committee of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact such other business as may properly come before the meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNGN:US $0.02 USD +0.002

TNGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNGN.
View Industry Companies
 

Industry Analysis

TNGN

Industry Average

Valuation TNGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TENGION INC, please visit www.tengion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.